Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Contineum Therapeutics, Inc. Class A ( (CTNM) ) just unveiled an update.
On May 14, 2025, Contineum Therapeutics filed a Shelf Registration Statement with the SEC to register the sale of up to $300 million in securities over a three-year period and entered a Sales Agreement with Leerink Partners for up to $75 million in Class A common stock. The company reported its first-quarter 2025 financial results, highlighting a cash runway projected through 2027 and increased research and development expenses due to the advancement of PIPE-791 and PIPE-307 programs. Contineum remains on track with its clinical milestones, expecting significant data readouts for its trials in 2025, which could impact its market positioning and stakeholder interests.
The most recent analyst rating on (CTNM) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Contineum Therapeutics, Inc. Class A stock, see the CTNM Stock Forecast page.
Spark’s Take on CTNM Stock
According to Spark, TipRanks’ AI Analyst, CTNM is a Underperform.
Contineum Therapeutics, Inc. receives a low stock score due to significant financial struggles, including a lack of revenue and negative profitability. The technical analysis reveals a bearish trend, and the valuation is weak with a negative P/E ratio. While there are some positives in terms of debt reduction and cash reserves, these are overshadowed by the company’s operational challenges and weak market momentum.
To see Spark’s full report on CTNM stock, click here.
More about Contineum Therapeutics, Inc. Class A
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology (NI&I) indications with significant unmet needs. The company is advancing a pipeline of internally-developed programs, including PIPE-791 and PIPE-307, which target conditions such as idiopathic pulmonary fibrosis, progressive multiple sclerosis, chronic pain, relapsing-remitting multiple sclerosis, and major depressive disorder.
Average Trading Volume: 68,028
Technical Sentiment Signal: Strong Sell
Current Market Cap: $99.09M
For an in-depth examination of CTNM stock, go to TipRanks’ Stock Analysis page.